Global Transcatheter Aortic Valve Replacement Market 2025-2035

Description

List of Tables

Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis Report by Product (Balloon-expandable valves, Self-expanding valves, and Mechanically-expanded valves) by Procedure (Transfemoral (TF), Transapical (TA), Transaortic (TAo), and Others) and by End User (Hospitals, Ambulatory Surgical Centers, and Others) Forecast Period (2025-2035)

Industry Overview

Transcatheter aortic valve replacement market size was valued at $6.8 billion in 2024 and is projected to reach $12.6 billion by 2035, growing at a CAGR of 5.9% during the forecast period (2025-2035). The market for aortic valve replacement is primarily driven by the rising prevalence of valvular diseases such as aortic stenosis and aortic regurgitation, in addition to technological improvements in the heart valve industry. Aortic stenosis is a highly widespread valve condition in the elderly population. The market for aortic valve replacement is primarily driven by the rising prevalence of valvular diseases such as aortic stenosis and aortic regurgitation, in addition to technological improvements in the heart valve industry. Aortic stenosis is the most frequent valve condition in the elderly population.

Market Dynamics

Technological Advancements

The TAVR market is fueled by significant innovations in valve design, delivery systems, and imaging technologies. The development of next-generation balloon-expandable and self-expanding valves with improved durability and reduced paravalvular leakages is enhancing procedural outcomes. Integration of advanced imaging tools and robotics is further streamlining procedural accuracy and safety.

Rising Prevalence of Cardiovascular Diseases

An increase in the global burden of aortic stenosis, particularly among the elderly population, is a primary growth driver. The growing preference for minimally invasive solutions among high-risk and intermediate-risk patients has made TAVR the standard of care in several countries.

Favorable Regulatory and Reimbursement Landscape

Supportive regulatory approvals and reimbursement policies, particularly in North America and Europe, are accelerating adoption rates. Expanding clinical indications from high-risk to low-risk patient groups have significantly broadened the treatment base.

Market Segmentation

Based on the product type, the market is segmented into balloon-expandable valves, self-expanding valves, and mechanically-expanded valves.
Based on the procedure, the market is segmented into transfemoral (TF), transapical (TA), transaortic (TAo), and others.
Based on the end user, the market is segmented into hospitals, ambulatory surgical centers, and others.

Balloon-Expandable Valves: The Largest Segment in Market Growth

By product type, the balloon-expandable valves segment is projected to lead the global transcatheter aortic valve replacement market with the largest share. These valves are increasingly preferred due to their ease of deployment, precision in placement, and suitability for a wide range of patients, including those with complex aortic anatomies. Technological advancements, such as enhanced valve durability and reduced paravalvular leakage, further strengthen their adoption. The rising prevalence of aortic stenosis globally, coupled with a growing geriatric population and increasing awareness of minimally invasive procedures, drives demand for balloon-expandable valves. Leading market players continue to invest in R&D to improve procedural outcomes, expand patient eligibility, and enhance post-implantation performance, ensuring sustained market dominance throughout the forecast period.

Hospitals: Key Segment in Market Growth

Among end-user segments, hospitals represent the key driver of growth in the global transcatheter aortic valve replacement market. The high adoption rate in hospitals is attributed to their advanced infrastructure, availability of skilled cardiologists, and capacity to handle complex procedures. Hospitals are increasingly equipped with hybrid operating rooms and cutting-edge imaging technologies, enabling safer and more efficient TAVR procedures. Moreover, hospitals are central to clinical trials, training, and adoption of next-generation valve technologies, further boosting the segment's contribution to market growth. Expanding healthcare infrastructure, particularly in emerging economies, along with rising cardiovascular disease prevalence, reinforces hospitals as a critical growth segment in the TAVR market.

Regional Outlook

The global transcatheter aortic valve replacement industry is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

India's Market Expands Rapidly in Asia-Pacific

India is emerging as a high-growth market for transcatheter aortic valve replacement (TAVR) in the Asia-Pacific region. Rapid advancements in healthcare infrastructure, increasing awareness of minimally invasive cardiac procedures, and rising prevalence of aortic stenosis are driving adoption. Government initiatives to enhance medical infrastructure, coupled with rising healthcare expenditure and growing access to advanced cardiac care, are fueling demand. The country's expanding middle-class population and higher disposable incomes support the affordability of TAVR procedures. Furthermore, increasing investments by domestic hospitals in cutting-edge cardiovascular technologies, along with collaborations with global device manufacturers, are positioning India as one of the fastest-growing TAVR markets in Asia-Pacific.

North America Maintains Strong Market Position

North America continues to dominate the global TAVR market, with the US holding the largest share. The region's market leadership is driven by advanced healthcare infrastructure, a large geriatric population, high prevalence of cardiovascular diseases, and strong insurance coverage. The US benefits from extensive clinical adoption of TAVR procedures, well-established cardiology centers, and strong R&D activities focused on next-generation valve technologies. Increasing awareness among patients and physicians about minimally invasive procedures, coupled with favorable reimbursement policies, further supports market growth. Key players in the region are investing heavily in product innovation, including balloon-expandable, self-expanding, and mechanically expanded valves, strengthening North America's position as a global TAVR hub.

Market Players Outlook

The major companies operating in the global transcatheter aortic valve replacement market include Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Medtronic Plc, JenaValve Technology, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In June 2025, Medtronic Plc launched its next-generation self-expanding TAVR valve, featuring improved hemodynamic performance and enhanced deliverability for complex anatomies.
In May 2025, Edwards Lifesciences received FDA approval for its latest balloon-expandable TAVR system, designed to reduce paravalvular leak and improve long-term durability.
In March 2025, Boston Scientific completed a strategic acquisition of a medical device startup specializing in mechanically-expanded valves, aiming to strengthen its TAVR portfolio.
In February 2025, JenaValve Technology, Inc. initiated a multicenter clinical trial for its novel transapical TAVR system targeting patients with bicuspid aortic valves.
In January 2025, Abbott Laboratories expanded its TAVR presence in emerging markets, including India and Latin America, through partnerships with leading cardiac centers.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global transcatheter aortic valve replacement market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023954

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Transcatheter Aortic Valve Replacement Market Sales Analysis - Product | Procedure | End User ($ Million)
Transcatheter Aortic Valve Replacement Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Transcatheter Aortic Valve Replacement Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Transcatheter Aortic Valve Replacement Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Transcatheter Aortic Valve Replacement Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Transcatheter Aortic Valve Replacement Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Transcatheter Aortic Valve Replacement Market Revenue and Share by Manufacturers
Transcatheter Aortic Valve Replacement Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Boston Scientific
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Edwards Lifesciences
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Medtronic Plc
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. JenaValve Technology, Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Transcatheter Aortic Valve Replacement Market Sales Analysis By Product ($ Million)

5.1. Balloon-expandable valves
5.2. Self-expanding valves
5.3. Mechanically-expanded valves

6. Global Transcatheter Aortic Valve Replacement Market Sales Analysis By Procedure ($ Million)

6.1. Transfemoral (TF)
6.2. Transapical (TA)
6.3. Transaortic (TAo)
6.4. Others (Trans-subclavian, Trans-axillary, and Transcarotid)

7. Global Transcatheter Aortic Valve Replacement Market Sales Analysis By End User ($ Million)

7.1. Hospitals
7.2. Ambulatory Surgical Centers
7.3. Others

8. Regional Analysis

8.1. North American Transcatheter Aortic Valve Replacement Market Sales Analysis - Product | Procedure | End User ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Transcatheter Aortic Valve Replacement Market Sales Analysis - Product | Procedure | End User ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Transcatheter Aortic Valve Replacement Market Sales Analysis - Product | Procedure | End User ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Transcatheter Aortic Valve Replacement Market Sales Analysis - Product | Procedure | End User ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Anteris Technologies
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Boston Scientific
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Direct Flow Medical
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Edwards Lifesciences
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. JenaValve Technology, Inc.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Lepu Medical Technology
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Medtronic Plc
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Meril Life Scienc
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. MicroPort Scientific Corp.
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. NaviGate Cardiac Structures
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Peijia Medical (Peijia Med)
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Venus Medtech
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Xeltis
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies